LY 117018
Latest Information Update: 30 Jul 2002
Price :
$50 *
At a glance
- Originator Eli Lilly and Company
- Class Antineoplastics; Pyrrolidines; Small molecules; Thiophenes
- Mechanism of Action Selective estrogen receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer; Menopausal syndrome; Postmenopausal osteoporosis
Most Recent Events
- 31 Mar 2000 Results of a preclinical study investigating the effect of LY 117018 on rat vaginal Candida albicans colonization has been added to the Women's Health pharmacodynamics section
- 18 Jan 2000 Preclinical development for Postmenopausal osteoporosis (Unknown route)
- 18 Jan 2000 Preclinical studies have been added to the Women's Health and Musculoskeletal pharmacodynamics sections (7166491 and 7166540)